Abstract
Symptom development in advanced castration-resistant prostate cancer (CRPC) patients can be attributed to local invasion of the tumor, metastasis to the bone, or compression of the spinal cord. Along the course of disease progression, 50–70% of the patients will eventually develop complications. Bone metastasis and consequent skeletal complications are the most common manifestations which may increase the risk of death from prostate cancer and decrease life quality. The clinical manifestations of bone metastasis include pain, skeletal-related events, and additional medical cost. Advancements in the understanding of the disease have resulted in the development of new palliation strategies. In this chapter, we examine several interventional options for local and systemic disease manifestation, bone-targeted palliative agents, and bone-targeted agents which potentially improve survival and management strategies for spinal cord compression. These treatments include various agents, namely, bisphosphonates, human monoclonal antibodies, and alpha- and beta-emitting radiopharmaceuticals.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Cameron MG, Kersten C, Guren MG, Fosså SD, Vistad I. Palliative pelvic radiotherapy of symptomatic incurable prostate cancer—a systematic review. Radiother Oncol. 2014;110(1):55–60.
Banning A, Sjogren P, Henriksen H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain. 1991;45(1):45–8.
Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9(3):509–24.
Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655–64.
Wagner G. Frequency of pain in patients with cancer. Recent Results Cancer Res. 1984;89:64–71.
Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25(5):805–13.
Tiedje LB, Kingry MJ, Stommel M. Patient attitudes concerning health behaviors during pregnancy: initial development of a questionnaire. Health Educ Q. 1992;19(4):481–93.
Pathological fractures due to bone metastases. Br Med J (Clin Res Ed). 1981;283(6294):748.
Galasko CS. The management of skeletal metastases. J R Coll Surg Edinb. 1980;25(3):144–61.
Lane MD, Le HB, Lee S, Young C, Heran MK, Badii M, et al. Combination radiofrequency ablation and cementoplasty for palliative treatment of painful neoplastic bone metastasis: experience with 53 treated lesions in 36 patients. Skelet Radiol. 2011;40(1):25–32.
Miles CL, Fellowes D, Goodman ML, Wilkinson S. Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2006;18(4):CD003448.
Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev. 2005;31(Suppl 3):19–25.
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–82.
Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345(13):948–55.
Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169(6):2008–12.
Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. Can J Urol. 2006;13(4):3180–8.
Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB. Bisphosphonates in oncology: rising stars or fallen heroes. Oncologist. 2009;14(2):181–91.
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.
Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940–5.
Roqué I, Figuls M, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2011;(7):CD003347.
Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357(9253):336–41.
Henriksen G, Fisher DR, Roeske JC, Bruland ØS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44(2):252–9.
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.
Grossman SA, Lossignol D. Diagnosis and treatment of epidural metastases. Oncology (Williston Park). 1990;4(4):47–54; discussion 55,58.
George R, Jeba J, Ramkumar G, Chacko AG, Leng M, Tharyan P. Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev. 2015;9:CD006716.
Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Koo, K.C. (2018). Palliative Care for Metastatic Symptomatic CRPC. In: Kim, C. (eds) Management of Advanced Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-6943-7_25
Download citation
DOI: https://doi.org/10.1007/978-981-10-6943-7_25
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-6942-0
Online ISBN: 978-981-10-6943-7
eBook Packages: MedicineMedicine (R0)